Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.48 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.48 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.48 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.48 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.48 |
| ▸ | GNAI3 | P08754 | 8/20 | 0.46 |
| ▸ | GNAI1 | P63096 | 8/20 | 0.46 |
| ▸ | GNAO1 | P09471 | 7/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | CES2 | O00748 | 1/20 | 0.41 |
| ▸ | CES1 | P23141 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15601957 | 0.94 | L3MBTL1 (0.60) | MEN1KMT2APOLBMAPTL3MBTL1 | |
| SCHEMBL24208230 | 0.87 | CHRNB2 (0.62) | MEN1KMT2APOLBMAPTL3MBTL1 | |
| SCHEMBL19154137 | 0.87 | CHRNB2 (0.62) | MEN1KMT2APOLBMAPTL3MBTL1 | |
| SCHEMBL12895626 | 0.83 | MEN1 (0.69) | MEN1KMT2APOLBMAPTL3MBTL1 | |
| SCHEMBL17350570 | 0.83 | GBA1 (0.54) | MEN1KMT2APOLBMAPTL3MBTL1 | |
| SCHEMBL21886617 | 0.82 | L3MBTL1 (0.51) | MEN1KMT2APOLBMAPTL3MBTL1 | |
| SCHEMBL13097061 | 0.82 | L3MBTL1 (0.60) | MEN1KMT2APOLBMAPTL3MBTL1 | |
| SCHEMBL27429184 | 0.82 | MEN1 (0.53) | MEN1KMT2APOLBMAPTL3MBTL1 | |
| SCHEMBL21140125 | 0.81 | GNAI3 (0.53) | MEN1KMT2APOLBMAPTL3MBTL1 | |
| SCHEMBL16281802 | 0.81 | L3MBTL1 (0.50) | MEN1KMT2APOLBMAPTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230127655-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-04-27 | — | — | US | disclosed |
| US-20230127655-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-04-27 | — | — | US | disclosed |
| EP-3882245-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | Vertex Pharmaceuticals Incorporated (US) | 2021-09-22 | — | — | EP | disclosed |
| EP-3327016-B1 | PREPARATION OF MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMA (US) | 2021-06-16 | — | — | EP | disclosed |
| EP-3327016-A1 | PREPARATION OF MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | Vertex Pharmaceuticals Incorporated (US) | 2018-05-30 | — | — | EP | disclosed |
| EP-3091011-B1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMA (US) | 2017-12-27 | — | — | EP | disclosed |
| US-9758510-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-09-12 | — | — | US | disclosed |
| US-20170189389-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-07-06 | — | — | US | disclosed |
| US-20160332997-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED | 2016-11-17 | — | — | US | disclosed |
| EP-3091011-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | Vertex Pharmaceuticals Inc. (US) | 2016-11-09 | — | — | EP | disclosed |
| US-20140329814-A2 | Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases | VERTEX PHARMA (US) | 2014-11-06 | — | — | US | disclosed |
| US-20140080826-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-03-20 | — | — | US | disclosed |
| US-20140057906-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-02-27 | — | — | US | disclosed |
| US-8623905-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-01-07 | — | — | US | disclosed |
| US-8575209-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-11-05 | — | — | US | disclosed |
| US-20130178471-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | Vextex Pharmaceuticals Incorporated (US) | 2013-07-11 | — | — | US | disclosed |
| CN-101253183-B | Process for preparing optically active diphosphanes | BASF SE | 2013-07-10 | — | — | CN | disclosed |
| US-8415387-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-04-09 | — | — | US | disclosed |
| US-20110098311-A1 | COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES | Vertex Pharmaceuticals Incorported (US) | 2011-04-28 | — | — | US | disclosed |
| CN-101253183-A | Process for preparing optically active diphosphanes | BASF SE (DE) | 2008-08-27 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140080826-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | MEN1 4687/4885KMT2A 4313/4885POLB 2183/4885 |
| US-20110098311-A1 | COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES | CFTR, SLC26A4, ABCB11 | MEN1 3122/4885KMT2A 4359/4885POLB 3770/4885 |
| US-20140329814-A2 | Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases | CFTR, SLC26A4, ABCB11 | MEN1 3122/4885KMT2A 4359/4885POLB 3770/4885 |
| US-20140057906-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | MEN1 4687/4885KMT2A 4313/4885POLB 2183/4885 |
| US-20160332997-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | MEN1 4687/4885KMT2A 4313/4885POLB 2183/4885 |
| US-20170189389-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | MEN1 4687/4885KMT2A 4313/4885POLB 2183/4885 |
| US-20130178471-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | MEN1 4687/4885KMT2A 4313/4885POLB 2183/4885 |
| US-20230127655-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | MEN1 4687/4885KMT2A 4313/4885POLB 2183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.